Investment Thesis
Equillium maintains a fortress balance sheet with $61.3M cash and minimal debt, supporting +13.9% YoY revenue growth, but profitability metrics are deteriorating sharply with -13.7% operating margins and diluted EPS declining 69.6% YoY, indicating unproven path to breakeven despite financial stability.
Strengths
- Fortress balance sheet with $61.3M cash comprising 97% of total assets and only 0.13x debt/equity ratio
- Positive revenue growth at +13.9% YoY demonstrating market traction and demand
- Exceptional liquidity with 18.62x current ratio providing substantial operational runway
Risks
- Deteriorating profitability with operating losses (-$5.6M) and -13.7% operating margin
- Significantly worsening diluted EPS (-69.6% YoY) suggesting accelerating losses despite revenue growth
- Negative operating and free cash flow (-$4.3M) indicating company is burning cash operationally
- Gross margin not disclosed, raising questions about unit economics and scalability
- Pharmaceutical sector execution risk with unproven commercial and pipeline development success
Key Metrics to Watch
- Operating cash flow trend and timeline to positive cash generation or breakeven
- Gross margin percentage and trajectory as revenue scales
- Year-over-year revenue growth sustainability and rate of deceleration
- Cash burn rate relative to cash runway remaining (currently ~14 years at constant burn)
- Operating expense growth rate versus revenue growth rate convergence
Financial Metrics
Revenue
41.1M
Net Income
-5.3M
EPS (Diluted)
$-0.06
Free Cash Flow
-4.3M
Total Assets
63.1M
Cash
61.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-13.7%
Net Margin
-12.9%
ROE
-8.9%
ROA
-8.4%
FCF Margin
-10.5%
Balance Sheet & Liquidity
Current Ratio
18.62x
Quick Ratio
18.62x
Debt/Equity
0.13x
Debt/Assets
5.7%
Interest Coverage
-11.43x
Long-term Debt
7.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:16:50.831290 |
Data as of: 2026-03-31 |
Powered by Claude AI